Joint Formulary & PAD

Tamsulosin hydrochloride - Benign prostatic hyperplasia

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Modified release capsules
Associated Icons :
SPC
Restrictions / Comments :
Preferred
 

Status 2

Non Formulary
Formulations :
  • Modified release tablets
Associated Icons :
NFD1
SPC
Restrictions / Comments :
Important
Use modified release capsules

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Tamsulosin hydrochloride
Indication :
Benign prostatic hyperplasia
Group Name :
Keywords :
BPH, LUTS, urinary tract symptoms, urinary frequency, urinary incontinence
Brand Names Include :
Flomax, Diffundox, Tabphyn, Flomaxtra
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0
Traffic Light Entries :
2

Other Indications

Below are listed other indications that Tamsulosin hydrochloride is used to treat.

  • No records returned.

Committee Recommendations (1)

Where an alpha blocker is indicated, the PCN recommend one of the following as a 1st-line treatment option:

  • Tamsulosin (modified release) – GREEN (NOTE - prescribe as generic capsules)
  • Doxazosin (immediate release) – GREEN (NOTE - XL / modified release preparations are considered BLACK)

Alfuzosin is more costly and is therefore not recommended as a 1st-line option.

Terazosin is reserved for patients with hepatic or renal failure since no dose adjustment is required in these patient groups.